Coronvirus company news summary – EU signs vaccine supply deal with Pfizer and BioNTech – RDIF announces Sputnik-V vaccine achieved 92% efficacy in Phase III trials

12 November 2020 (Last Updated November 12th, 2020 09:01)

12 November 2020 

Sagent Pharmaceuticals, a subsidiary of the Nichi-Iko Group, announced the launch its Phase II trial of Camostat Mesilate (Camostat) to test its efficacy and safety for treating high-risk Covid-19 patients. The company has begun enrolling patients for the trial.

The Russian National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund announced that the Sputnik V vaccine, demonstrated 92% efficacy in its Phase III Covid-19 trials. The studies enrolled 40,000 volunteers in Russia.

Pfizer and BioNTech signed an agreement to supply 200 million doses of its BNT162b2 mRNA-based vaccine against Covid-19 to European Union (EU) member states. The agreement also allows the European Commission to request an additional 100 million doses of the vaccine. The vaccines are expected to be delivered by the end of 2020, after thorough clinical success and regulatory authorisation.

Mateon Therapeutics, a developer of TGF-β therapeutics, announced that it has entered into a definitive agreement with contract manufacturer Windlas Biotech to market the ARTIVeda, Mateon's leading ethnobiology drug, to fight Covid-19. Early clinical studies have demonstrated the drug's safety and efficacy.